课题基金 / 基金详情

REGULATION OF GTP-BINDING PROTEINS

REGULATION OF GTP-BINDING PROTEINS
GTP 结合蛋白的调节
批准号:
6541673
负责人:
MARTHA VAUGHAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

MARTHA VAUGHAN的其他基金

相似基金

相关文献

中文摘要
翻译
ARF功能需要GTP结合的活性形式和GDP结合的非活性形式之间的调节交替。GTP结合由鸟嘌呤核苷酸交换蛋白(GEP)催化,GTP酶激活蛋白(GAP)失活。大多数这些研究中涉及的两种一般类型的GEP是被BFA抑制的~200 kDa蛋白质和较小的~50 kDa GEP。BFA是一种可逆地干扰蛋白质分泌并导致高尔基池解体的药物。所有的GEP都有大约200个氨基酸组成的所谓Sec7结构域,负责GEP的活性及其对BFA的敏感性。该小组早些时候从牛脑中纯化了两个BFA抑制的GEP(BIG1和BIG2),它们在凝胶过滤中表现为约670 kDa的分子。与特定的、亲和纯化的抗肽抗体的免疫沉淀表明,它们在很大程度上是相同的大分子复合体的组成部分。通过与整合素的相互作用而克隆的50 kDa细胞粘附素-1已被该小组证明是BFA不敏感的ARF GEP。由独立的cDNA克隆预测的细胞粘附素-2的氨基酸序列仅在存在或不存在单一甘氨酸的情况下不同。该小组证明了存在两种不同的信使核糖核酸亚型,对已知的三种细胞粘附素中的每一种都有相同的不同方式,并发现了一种新的只有一种信使核糖核酸的细胞粘附素-4。为了阐明控制甘氨酸单链插入的机制(S),比较了细胞粘附素-1和细胞粘附素-4的基因,发现除了细胞粘附素-1的一个额外的3个碱基的外显子外,两个基因在结构上有显著的相似性。额外的甘氨酸改变了PH结构域的结构,导致细胞粘附素与特定的磷脂酰肌醇相互作用的显着差异。调节细胞粘附素1、2和3的选择性剪接以及单个细胞粘附素的细胞特异性表达的机制正在研究中。在其他研究中,一个不同于已知的新的ARF GEP被克隆和鉴定。~100-kDa蛋白含有在所有ARF GEP中发现的sec7结构域,但不共享其他识别的结构域。它的活性不受布雷菲尔丁A或磷脂的影响,似乎优先作为ARF6的GEP发挥作用。该基因在外周血细胞、脑和脾中含量特别丰富。免疫反应阳性的内源性ARF6和新的GEP100部分共存于囊泡结构,GEP免疫荧光与早期内体标记EEA-1的免疫荧光也一致。ADP-核糖化因子结构域蛋白1(ARD1)最初是在实验室克隆的,与其他ARF不同的是,它存在一个46 kDa的氨基末端延伸(P5),它是其ARF结构域(P3)的GTP酶激活蛋白(GAP)。与ARF GAP类似,ARD1的GAP结构域包含对活性至关重要的锌指基序和精氨酸残基。它与其他ARF GAP的不同之处在于它与GTP结合域的共价结合以及它对ARD1ARF结构域的GAP活性的特异性。ARF被认为在细胞内运输囊泡的形成和它们从一个隔室到另一个隔室的移动中发挥关键作用。过表达和内源性ARD1都与高尔基体和溶酶体膜相关,这与溶酶体的形成或功能以及高尔基体和溶酶体间的蛋白质转运相一致。在酵母双杂交筛选中发现了ARD1与细胞粘附素-1的相互作用。细胞粘附素-2在这一系统中不能相互作用,与细胞粘附素-1相比,细胞粘附素-2对ARD1的GEP活性要低得多,尽管它们与ARF1一样活跃。在体外也显示了优先的物理相互作用,并鉴定了负责细胞粘附素-1/ARD1相互作用专一性的残基。ARD1基因敲除的小鼠终于在今年被获得,这种蛋白质的生理功能的新线索正在出现。
英文摘要
ARF function requires the regulated alternation between GTP-bound active and GDP-bound inactive forms. GTP binding is catalyzed by guanine nucleotide-exchange proteins (GEPs) and inactivation by GTPase-activating proteins (GAPs). Two general types of GEPs that have been involved in most of these studies are ~200-kDa proteins that are inhibited by BFA (a drug that reversibly interferes with protein secretion and causes disintegration of Golgi cisternae) and smaller ~50-kDa GEPs that are BFA-resistant. All GEPs have so-called Sec7 domains of ~200 amino acids that are responsible for the GEP activity, as well as its BFA sensitivity. The group had earlier purified, from bovine brain, two BFA-inhibited GEPs (BIG1 and BIG2) that behaved on gel filtration as molecules of ~670 kDa. Immunoprecipitation with specific, affinity-purified anti-peptide antibodies demonstrated that they are to a large extent components of the same macromolecular complexes. The 50-kDa cytohesin-1, cloned by its interaction with integrin, had been shown by the group to be a BFA-insensitive ARF GEP. Amino acid sequences for cytohesin-2 predicted by independent cDNA clones differ only in the presence or absence of a single glycine. The group demonstrated the existence of two mRNA isoforms that differ in the same way for each of three known cytohesins and identified a new cytohesin-4 with only one mRNA. To elucidate mechanism(s) that control the single glycine insertion, genes for cytohesin-1 and -4 were compared, revealing remarkable similarity of structure except for an extra 3-bp exon in cytohesin-1. The extra glycine alters PH domain structure resulting in significant differences in cytohesin interaction with specific phosphoinositides. Mechanisms that regulate the alternative splicing of cytohesins 1, 2, and 3, as well as the cell-specific expression of individual cytohesins are being investigated. In other studies, a novel ARF GEP, unlike any already known, was cloned and characterized. The ~100-kDa protein contains the Sec7 domain found in all ARF GEPs, but shares no other recognized domain structures. Its activity is not affected by brefeldin A or phospholipids, and it appears to function preferentiallly as a GEP for ARF6. The mRNA is particularly abundant in peripheral blood leukocytes, brain, and spleen. Immunoreactive endogenous ARF 6 and the new GEP100 were partially co-localized in vesicular structures and the GEP immunofluorescence also coincided with that of EEA-1, a marker for early endosomes. ADP-ribosylation factor domain protein 1 (ARD1), initially cloned in the laboratory, differs from other ARFs by the presence of a 46-kDa amino-terminal extension (p5), which acts as a GTPase-activating protein (GAP) for its ARF domain (p3). Similar to ARF GAPs, the GAP domain of ARD1 contains a zinc finger motif and arginine residues that are critical for activity. It differs from other ARF GAPs in its covalent association with the GTP-binding domain and the specificity of its GAP activity for the ARF domain of ARD1. ARFs are presumed to play a key role in the formation of intracellular transport vesicles and in their movement from one compartment to another. Both overexpressed and endogenous ARD1 were associated with Golgi and lysosomal membranes, consistent with a role in the formation or function of lysosomes and in protein trafficking bettween Golgi and lysosomes. Interaction of ARD1 and cytohesin-1 was found in a yeast two-hybrid screen. Cytohesin-2 failed to interact in this system and had much less GEP activity toward ARD1 than did cytohesin-1, although they were equally active with ARF1. Preferential physical interaction was also shown in vitro and residues responsible for specificity of the cytohesin-1/ARD1 interaction were identified. ARD1 "knock-out" mice were finally obtained this year and new clues to the physiological function of this protein are emerging.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GTP-BINDING PROTEIN STRUCTURE/FUNCTION STUDIES
Molecular And Biochemical Characterization Of GTP-bindin
Regulation Of GTP-binding Proteins
Molecular Characterization and Regulation of GTP-binding Proteins
海外基金